Vertaile menetelmiä
Tarkastele valitsemiasi menetelmiä rinnakkain; eroavat rivit korostetaan.
| TED-QoL / GO-QoL: Kilpirauhasen silmäsairauden elämänlaatu-kysely× | Basedowin taudin oireiden tarkistuslista× | |
|---|---|---|
| Tieteenala | Endokrinologia | Endokrinologia |
| Menetelmäperhe | Process / pipeline | Process / pipeline |
| Syntyvuosi≠ | 2001 | 1997 |
| Kehittäjä≠ | Caroline Terwee, Markus Gerding, Frank Dekker | Multiple authors; consensus from Endocrine Society |
| Tyyppi≠ | Patient self-report questionnaire | Patient self-report symptom checklist |
| Alkuperäislähde≠ | Terwee, C. B., Gerding, M. N., Dekker, F. W., et al. (2001). Development of a disease-specific questionnaire for patients with Graves' ophthalmopathy: The GO-QoL. Br J Ophthalmol, 82(7), 773-779. link ↗ | Engel, G. L., Dayan, A. D., Thorn, G. W., et al. (1997). Hyperthyroidism: A multisystem disease with diverse manifestations. Adv Intern Med, 42, 55-91. link ↗ |
| Rinnakkaisnimet | GO-QoL, Graves Ophthalmopathy Quality of Life | HSC, Hyperthyroid Symptom Inventory |
| Liittyvät | 3 | 3 |
| Tiivistelmä≠ | The TED-QoL (also known as GO-QoL, Graves' Ophthalmopathy Quality of Life questionnaire) is a 16-item disease-specific instrument assessing quality of life impacts in patients with thyroid eye disease (TED), the ophthalmologic manifestation of Graves' disease. Developed by Terwee, Gerding, and colleagues in 2001, it captures both functional vision limitations and psychological distress related to the characteristic eye changes (exophthalmos, lid retraction, diplopia, appearance concerns). It is the gold-standard outcome measure for TED quality of life assessment. | The Hyperthyroidism Symptom Checklist is a structured assessment tool for quantifying the symptom burden of Graves' disease and other thyrotoxicosis conditions. It captures the multisystem manifestations of excess thyroid hormone: cardiovascular (palpitations, tachycardia, arrhythmia), neuropsychiatric (anxiety, tremor, insomnia), metabolic (heat intolerance, weight loss, appetite), and eye-specific symptoms (in Graves' ophthalmopathy). Used in endocrinology practice and clinical trials to monitor disease activity and treatment response. |
| ScholarGateAineisto ↗ |
|
|